Subject(s)
Anticoagulants/administration & dosage , Atrial Fibrillation/drug therapy , Coumarins/administration & dosage , Thromboembolism/prevention & control , Venous Thrombosis/drug therapy , Administration, Oral , Adult , Aged , Aged, 80 and over , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Coumarins/adverse effects , Coumarins/therapeutic use , Female , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Humans , International Normalized Ratio , Male , Middle Aged , Patient Education as Topic , Prothrombin Time , Recurrence , Retrospective Studies , Self Administration , Surveys and Questionnaires , Thromboembolism/epidemiology , Thromboembolism/etiology , Treatment OutcomeABSTRACT
PURPOSE: To determine the systemic effects of local fibrinolytic therapy with low-dose recombinant tissue-type plasminogen activator (rt-PA). METHODS: Ten patients received intrathrombal infusion of 20 mg rt-PA and heparin for local thrombolysis and had subsequent percutaneous transluminal angioplasty (PTA). Eight controls underwent PTA and received heparin alone. We measured t-PA, D-Dimer, and fibrinogen levels before, directly after, and 20, 40, and 60 min and 24 hr after therapy. RESULTS: In the thrombolysis group the t-PA level peaked immediately after infusion and then declined within 1 hr. D-Dimer increased and remained elevated, whereas in the control group only t-PA levels increased, and only after 24 hr. Fibrinogen remained within the normal range in both groups. Eight of ten patients in the thrombolysis group and seven of eight with PTA had clinical improvement after the procedure. CONCLUSIONS: The increase in D-Dimer in the rt-PA group indicates a good local fibrinolytic effect. The fact that fibrinogen levels remained unchanged indicates that there is a lack of systemic fibrinogenolysis.
